Spironolactone prescribing in heart failure: comparison between general medical patients and those attending a specialist left ventricular dysfunction clinic. by McMullan, R. & Silke, B.
The Ulster Medical Journal, Volume 70, No. 2, pp. 111-115, November 2001
Spironolactone prescribing in heart failure:
Comparison between general medical patients and those attending a
specialist left ventricular dysfunction clinic
R McMullan, B Silke
Accepted 1 August 2001
SUMMARY
We compared the rate of prescription of low-dose spironolactone among patients with heart
failure in a general medical inpatientsetting and in a specialist left ventricular (LV) dysfunction
clinic. 38% of general medical patients and 72% of patients attending the specialist clinic had
beenprescribedspironolactone. Whencontraindications wereconsidered, 54% ofpatientsinthe
general medical group and 77% of patients in the specialist clinic group were appropriately
treated in respect ofspironolactone prescribing. Patients attending a specialist LV dysfunction
clinicarethereforemorelikelytobetreatedwithlowdosespironolactone,anacceptedappropriate
treatment for heart failure, than those admitted to general medical and acute geriatric
units.Improvement in care for patients with CHF may be achieved either by increasing the use
ofspecialist clinics or by better dissemination ofevolving evidence.
INTRODUCTION
In September 1999, the findings of the
Randomized Aldactone Evaluation Study'
(RALES) were published. In this double-blind
study, 1663patientswithleftventricularejection
fraction less than 35%, an( NYHA symptom
class III-IV were randomised to receive either
25mg spironolactone or placebo. The study was
discontinuedprematurelyaftertwoyearsbecause
interim analysis showed a 30% reduction in risk
of death in the group receiving spironolactone.
This is equivalent to a number needed to treat of
nine to avoid one death during this two year
period2. Inaddition, therewasa35%reductionin
riskofhospitalisation forworseningheartfailure
(equivalenttoanumberneededtotreatofeleven)
andsignificantsymptomaticimprovementinthis
group. The low cost of spironolactone implied
likely cost-effectiveness.
RALES therefore defined a standard in heart
failure management having demonstrated an
important contribution from low dose
spironolactone in addition to conventional
therapies. We appreciate the importance of
applying evidence from clinical studies to
practice, and it is therefore reasonable to aim to
incorporate spironolactone into the medication
of all patients with moderate to severe heart
failure, except for the few in whom it is
contraindicated. We accept that there is no
evidence available atpresentto supportits use in
mild CHF.
We wished to assess the performance of the
specialistleftventricular(LV)dysfunctionclinic
at the Belfast City Hospital with respect to
spironolactone prescribing, comparing this
against the prescribing rates for inpatients
admitted tothegeneral medical andacute elderly
care units.
METHOD
Therecords ofthelast50patients whosehospital
admission was codedwith aprimary diagnosis of
heartfailurewereanalysedpriorto20thFebruary
2000. The 'final' chartrelated to an admission in
December 1999. Wealsoreviewedtherecords of
all 75 patients who were attending the LV
dysfunction clinic during the same period. The
assumption was made that patients admitted to
hospital on the emergency "take-in" due to heart
failure and those referred to the specialist clinic
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would be unlikely to have mild CHF, and that
almost allcouldbeconsideredtohavemoderate-
to-severe disease, meriting spironolactone
therapy.
Datacollectedforthepurpose ofthis study were:
1. Whether the patient was receiving
spironolactone
2. Ifnot,whethertherewasanycontraindication.
We identified three major contraindications,
modelling these on those applied in the
RALES1: serumcreatinine>221umol/l, serum
potassium >5.Ommol/l and hepatic failure.
RESULTS
Of the 50 general medical inpatients studied,
38% were on spironolactone. Of the remaining
patients who were not receiving this drug 26%
had at least one contraindication, while 74%
were without clear contraindication (Tables I &
II and Figure 1). It can therefore be concluded
that 46% ofthese 50 patients were not receiving
spironolactone without contraindication.
Ofthe 75 patients attending the LV dysfunction
clinic, 72% were receiving spironolactone. Of
those who were not, 19% had at least one
contraindication, and 81% had no identifiable
contraindication (Tables I & II and Figure 2).
Therefore 23% of these 75 patients were not
receiving spironolactone despite the absence of
clear contraindication.
DISCUSSION
Thecomparisonsbetweenthetwo setsofdataare
interesting but in some ways surprising. Patients
who attended the LV dysfunction clinic were
more likely to have been prescribed
spironolactone; perhaps this is to be expected
since physicians running a specialist clinic are
probably more likely to be aware of recent
evidence within theirdiscipline. However, when
thegroupwhichwasnotprescribedspironolactone
in each case is examined, it becomes clear that
there is little difference in the reason for its
omission. One might have expected that the
proportion of patients not receiving
spironolactone due to contraindication (rather
than oversight or lack offamiliarity with current
evidence) wouldhavebeengreateramongtheLV
dysfunction clinic patients; this was notthe case.
The absolute risk of 'oversight', however, was
greater among the general medical patient
TABLE I:
Incidence oflow dose spironolactone
prescribing in heartfailurepatients in both
settings.
General LV
Medical Dysfunction
Inpatients Clinic
Number of patients on
spironolactone 19/50(38%) 54/75(72%)
Number ofpatients not on
spironolactone 31/50(62%) 21/75 (28%)
TABLE II:
Proportion ofpatients with and without
contraindication among those not receiving
spirono actone in each setting.
General LV
Medical Dysfunction
Inpatients Clinic
Number not on spironolactone
with contraindication 8/31 (26%) 4/21 (19%)
Number not on spironolactone
without contraindication 23/31 (74%) 17/21 (81%)
population.
THE ROLE OF ALDOSTERONE ANTAGONISM IN
HEART FAILURE
Aldosterone has an established role in the
pathophysiology ofleft ventricular dysfunction.
About 30% ofpatients with chronic heart failure
(CHF)havediastolicdysfunctioninthesettingof
normal ornearnormal systolic function.3 In such
patients, collagen matrix withinthemyocardium
is felt to be the major culprit producing diastolic
dysfunction by way of increasing myocardial
stiffness. Such fibrotic infiltration also impairs
systolic function and contributes to the
developmentofconductiondefectsandassociated
arrhythmias.4
Inadditiontocollagen, cardiacfibroblastsproduce
matrix metalloproteinase, an enzyme which
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degradesinterstitialcollagen; thesecellsareunder
theinfluenceoftherenin-angiotensin-aldosterone
system (RAAS).3 Animal studies have
demonstrated increased fibrosis in the setting of
hyperaldosteronism and the absence of fibrosis
whenactivationoftheRAAShasbeenprevented.
Furthermore, aldosterone stimulates collagen
synthesisinculturedcardiacfibroblastsinadose-
dependentmanner. Inanimalstudies,inthesetting
of primary or secondary hyperaldosteronism,
spironolactone has been shown to prevent
myocardial fibrosis.
High serum aldosterone is a characteristic of
CHF, with up to 40% ofpatients on Angiotensin
Converting Enzyme (ACE) Inhibitors having
persistentlyraisedlevels.5Inadditiontoimpairing
cardiac function by way of causing fibrosis,
aldosterone may further increase the
arrhythmogenicityofthismilieuviainhibitionof
cardiac noradrenaline reuptake, increased
sympathetic activity, decreasedparasympathetic
tone and impairment of baroreceptor-mediated
heart rate variability.6
Spironolactone has been found to decrease the
amount of a key marker of vascular collagen
turnover and also to bring about a decrease in
heartrate.4Interestingly, this beneficial decrease
inheartratewasmostprominentinearlymorning
when fatal cardiac events are known to be most
common.
Spironolactone has also been shown to improve
vascular endothelial dysfunction (characterised
byimprovedresponsivenesstovasoactiveagents)
and also to inhibit the conversion ofangiotensin
I to angiotensin 11.7 Perhaps such effects may
account at least in part for the mortality benefits
of aldosterone antagonism identified in the
RALES1.
It is therefore well established that
hyperaldosteronism has an adverse effect on
cardiac function, one which may be avoided by
the use of aldosterone antagonists. For many
years it has been assumed that since ACE
inhibitors block aldosterone production
spironolactone is unnecessary8; however, the
finding that it reduced mortality by 30% over a
two-year period with concomitant reduction in
morbidity mustnotbeignored. Itshouldbenoted
that spironolactone is a useful adjunct to, but not
substitution for, ACE inhibitor therapy. Indeed
thereisafeelingthatthebenefitsofspironolactone
arelikelytobelostifapatientisnotconcomitantly
receiving an ACE inhibitor.
In RALES1, the major adverse effects of
spironolactone in men were gynaecomastia and
breast pain, occurring in 10% of the treatment
group and in only 1% of the placebo group. Of
note, serious hyperkalaemiawas minimalinboth
groups. In support of this, another study found
that adding spironolactone to conventional
therapy resulted in no significant increase in
serum urea, creatinine or potassium.9 We might,
therefore reasonably consider spironolactone to
be a safe drug.
CHF is a major public health issue, with general
prevalence estimated at 0.4-2.0% in the UK;
among the elderly this rises to 10%.1o Ittherefore
carries significant implications for resource
allocationanditislogicalthatinterventionswhich
reduce associated hospitalisations should be
considered important.
The cost of a one-year supply of spironolactone
is typically £32.85 per patient. Estimation ofthe
total number of patients with CHF in Northern
Ireland is fraught with difficulties. Based on
extrapolation of Framingham data, the figure
could be expected to be between 10000 and
11000. We attempted to corroborate this with an
alternative method involving division of the
annual number of defined daily doses (DDD) of
loop diuretics prescribed by the number of days
in the year. This proved unreliable, yielding a
figure in excess of 30 000; it failed to exclude
patients who would bereceiving these agents for
reasons otherthan CHFanditdidnotaccountfor
the many CHF patients who receive doses much
greater than the DDD (40mg for frusemide and
1mg for bumetanide).
If we assume that at least 6000 patients in
Northern Ireland have moderate-to-severe CHF
andarewithoutcontraindicationtospironolactone
therapy, then the cost of treating such a group
would be approximately £200000 per annum.
Predictingcost-effectivenessiscomplexanddata
producedisunlikelytobeveryreliable,however,
a guarded estimate can be made. If one applies
the reduction in CHF-associated admissions
observedbythe RALES investigators (35%) and
theestimatethat21.9%ofpatientswithmoderate-
to-severe CHFrequirehospitalisation per annum
as determined by the SOLVD investigators11,
then of a predicted 1300 admissions per year,
around 450 could be avoided. Based on 1997
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BelfastCityHospitalfigures, onesuchadmission
costs on average £2436. The potential saving is
around £1.1million with an outlay of £200,000;
the net saving could therefore be as much as
£900,000.Eveniftheseestimatesareexaggerated,
itseems likelythat, withappropriateprescribing,
savings on hospitalisation expenditure could
negate the cost of any years of life saved.
Spironolactone is the latest addition to several
advocatedconstituentsofaCHFtreatmentregime;
however, based on past performance it would
seem likely that its widespread incorporation
will be a slow process. Reluctance to move
practice patterns inphase with new evidence has
limited CHF management in the UK. Despite an
abundance of evidence favouring outcome
benefits and cost-effectiveness achievable by
appropriateuseofACEinhibitors, thereisagreat
deal of data to indicate that the 80-90% rates of
toleranceestimatedinthemajormortalitystudies
arepoorlyreflectedinprescribingpatterns.Davie
and McMurray'2 reported ACE inhibitor
prescribing rates of around 66% in hospital and
data gathered in 1994 in a community setting in
NorthernIrelandestimatedthatperhaps asfew as
18% ofCHF patients were on such an agent.10 In
a survey of general practitioners' attitudes to
CHF management13, it became apparent that
reluctancetoprescribeACEinhibitors wasmuch
more strongly related to fear of causing harm
than ignorance ofprovenbenefits (ofwhich 98%
were aware).
Interesting data are available suggesting that
reluctance to prescribe in CHF is variable
throughoutEurope'4 . TheUKtypicallydisplay a
lowerrateofprescription,particularlywithregard
to digoxin and beta-adrenoceptor antagonists.
One might expect, therefore, that the rate of
prescription ofspironolactone will also be lower
than average in this country.
Our small study suggests thatpatients with heart
failure who are managed at a specialist LV
dysfunction clinic are more likely to receive
spironolactone than those who are managed as
inpatients inthegeneralmedicaland acuteelderly
care units. It also highlights that even in the
specialist clinic setting there is room for
improvement.Admittedly,thestudyisnotwithout
flaw: thereisimbalancein thenumberofpatients
ineachgroupandinsomecases, clinicaldecisions
(such as to withhold agiven treatment) may have
been based on observations and measurements
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not documented. It is not appropriate to
presumptivelyextrapolatethesefindings toother
heartfailuretreatmentinterventions,nortoimply
actual outcome differences between the two
groups; however, ourfindings support in at least
one facet the argument for having teams with a
special interest in managing patients with heart
failure. This is further supported by data from
Chin et all' identifying an analogous situation
relating to ACE inhibitor therapy, whereby
generalpractitioners andgeneralphysicianswere
found to underuse these drugs whencompared to
cardiologists.
CONCLUSION
Low dose spironolactone hasbeenidentified as a
safe and rational therapy which decreases
mortality, improves symptoms and reduces
hospitalisations (thus producing resource
utilisation benefits) when added to conventional
treatment in patients with moderate-to-severe
CHF. When measured against this standard, the
finding that we adequately treat only 54% of
heartfailurepatientsinageneralmedicalinpatient
setting and 77% ofpatients attending a specialist
LV dysfunction clinic provides us with a point
from which we might expect to improve; one
might alternatively reason that this reflects
surprisinglyimpressivereceptivenesstonewdata
over a relatively short time. We have a duty to
raise the standard ofcare for patients with CHF,
eitherbyincreasingtheuseofspecialistclinicsor
by improving general physicians' awareness of
evolving evidence.
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